Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

TAVI benefits were attenuated and mortality trended higher in PARTNER 3 at 5 years. For Evolut, TAVI maintained an edge.

Related Keywords

Boston ,Massachusetts ,United States ,New York ,Houston ,Texas ,Gilbert Tang ,Pinak Shah ,David Cohen ,Michael Reardon ,Edwards Lifesciences ,Kendra Grubb ,Bernard Prendergast ,Drug Administration ,Md Emory University ,Presbyterian Columbia University Irving Medical Center ,Md Cardiovascular Research Foundation St ,Md Methodist Debakey Heart Vascular Center ,Journal Of The American College Cardiology ,Mount Sinai Health System ,Columbia University Irving Medical Center ,New England Journal ,Emory University ,Evolut Low Risk ,Methodist Debakey Heart ,Vascular Center ,Sapien Ultra ,Cleveland Clinic London ,Cardiovascular Research ,Francis Hospital ,American College ,Evolut Low Risk Trial ,